Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...

CHEST guidelines on biologic management in severe adult asthma offers recommendations on choosing and switching among biologic therapies.

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

IN 2010 AN American girl called Emily Whitehead developed a form of leukaemia that is usually terminal. She was five years old. Two years later, she became the first paediatric patient to be offered a ...

Objective Systemic corticosteroids for 5–7 days are standard care for asthma exacerbations, but the optimal duration and ...

Around 88% of primary care providers managing patients with uncontrolled asthma reported being unfamiliar or only somewhat ...

The authors write that once severe asthma is diagnosed, clinicians should determine asthma endotype (Type2-high or Type2-low) to help choose the best therapy for the patient. Asthma endotype, clinical ...

The new asthma treatment that could ‘transform lives’ - The injection is recommended as an additional maintenance treatment for patients over 12 when usual medications have not proven effective enough ...